Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Related

A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018
Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies
Jeffrey S. Heier, MD
Updates from the Field
2020
Endolaserless Vitrectomy with Intravitreal Aflibercept
Dennis M. Marcus, MD
Updates from the Field
2017

Category: AMD-Neovascular

See more